About: An Update on Current Therapeutic Drugs Treating COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: An Update on Current Therapeutic Drugs Treating COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	An Update on Current Therapeutic Drugs Treating COVID-19
Creator	Liu, Xia Liu, Zhigang Amorosa, Louis Brunetti, Luigi Chou, Jordan Hudlikar, Rasika Kong, Ah-Ng Kuo, Hsiao-Chen Li, Shanyi Peter, Rebecca Pochung, & Poiani, George Shannar, Ahmad Wang, Lujing Wu, Renyi
source	Medline; PMC
abstract	The current pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has presented unprecedented challenges to the healthcare systems in almost every country around the world. Currently, there are no proven effective vaccines or therapeutic agents against the virus. Current clinical management includes infection prevention and control measures and supportive care including supplemental oxygen and mechanical ventilatory support. Evolving research and clinical data regarding the virologic SARS-CoV-2 suggest a potential list of repurposed drugs with appropriate pharmacological effects and therapeutic efficacies in treating COVID-19 patients. In this review, we will update and summarize the most common and plausible drugs for the treatment of COVID-19 patients. These drugs and therapeutic agents include antiviral agents (remdesivir, hydroxychloroquine, chloroquine, lopinavir, umifenovir, favipiravir, and oseltamivir), and supporting agents (Ascorbic acid, Azithromycin, Corticosteroids, Nitric oxide, IL-6 antagonists), among others. We hope that this review will provide useful and most updated therapeutic drugs to prevent, control, and treat COVID-19 patients until the approval of vaccines and specific drugs targeting SARS-CoV-2.
has issue date	2020-05-11(xsd:dateTime)
bibo:doi	10.1007/s40495-020-00216-7
bibo:pmid	32395418
has license	no-cc
sha1sum (hex)	624560cb35b61e7c2b38aa294d409a8c85644d4f
schema:url	https://doi.org/10.1007/s40495-020-00216-7
resource representing a document's title	An Update on Current Therapeutic Drugs Treating COVID-19
has PubMed Central identifier	PMC7211915
has PubMed identifier	32395418
schema:publication	Curr Pharmacol Rep
resource representing a document's body	covid:624560cb35b61e7c2b38aa294d409a8c85644d4f#body_text
is schema:about of	named entity 'acid' named entity 'potential' named entity 'oxygen' named entity 'patients' named entity 'patients' named entity 'UMIFENOVIR' named entity 'ANTIVIRAL AGENTS' named entity 'SPECIFIC' named entity 'UPDATE' named entity 'AZITHROMYCIN' named entity 'PANDEMIC' named entity 'USEFUL' named entity 'CONTROL' named entity 'TREATING' named entity 'COUNTRY' named entity 'ACID' named entity 'EFFECTIVE' named entity 'LIST' named entity 'MEASURES' named entity 'REVIEW' named entity 'control' named entity 'therapeutic drugs' named entity 'caused' named entity 'clinical management' named entity 'patients' named entity 'COVID' named entity 'hydroxychloroquine' named entity 'supportive care' named entity 'healthcare systems' named entity 'vaccines' named entity 'SARS-CoV-2' named entity 'ventilatory support' named entity 'therapeutic agents' named entity 'favipiravir' named entity 'pharmacological' named entity 'drugs' named entity 'cytokines' named entity 'HIV-1 protease' named entity 'lysosomes' named entity 'NL63' named entity 'organ transplant rejection' named entity 'COVID' named entity 'hydroxychloroquine' named entity 'tocilizumab' named entity 'C-protein' named entity 'pulmonary artery pressure' named entity 'vitamin' named entity 'HCV' named entity 'COVID-19 pandemic' named entity 'arthritis' named entity 'chest CT scan' named entity 'alveolar capillaries' named entity 'nausea' named entity 'interleukin' named entity 'IL-6' named entity 'sirolimus' named entity 'Chinese University of Hong Kong' named entity 'remdesivir' named entity 'IL-1β' named entity 'expanded access' named entity 'HIV-1 protease' named entity 'antiviral therapy' named entity 'COVID' named entity 'arthritis' named entity 'acute respiratory failure' named entity 'IV infusion' named entity 'transfusion'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software